In an ALS study, growth factor FGF4 reduced the activity of star-shaped cells called astrocytes but did not stop motor ...

Differences in human tears in ALS can distinguish bulbar-onset disease from spinal-onset ALS, making this a possible ...

Modality.AI and Target ALS are partnering on a clinical study of AI as a way to assess changes in speech and motor function ...

Changes in the production of several immune proteins at the time of an ALS diagnosis were linked to disease progression in ...

The new patent covers Neurosense's formulation of PrimeC, a fixed-dose combo of an approved antibiotic and anti-inflammatory.

Columnist Juliet Taylor chats with Roon CEO and co-founder Vikram Bhaskaran about this new ALS app designed for patients and ...

Mabylon has received grants from Target ALS and the ALS Association to develop human-derived antibodies to help restore ...

A group of eight molecules in the blood can be used as a biomarker to distinguish ALS from other neurodegenerative conditions ...

The Mayo Clinic was awarded $12 million to support a study that will give ALS patients access to the investigational therapy ...

A $500,000 MDA research grant to a Mass General investigator will support the HEALEY ALS platform trial that's testing ...

What is contentment, and is it even possible with the daily struggles of ALS? Columnist Kristin Neva offers her observations as a caregiver.

Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to get ...